PURPOSE: Conjunctival hyperemia (CH) occurs through vasodilation reactions in the conjunctiva. Existing treatments, including ocular vasoconstrictors and antihistamines, provide temporary relief; however, continued use has been associated with tachyphylaxis and adverse events. This study explored healthcare professionals' (HCPs) experience treating CH and satisfaction with available treatments, including brimonidine tartrate (0.025%), an ophthalmic decongestant available over the counter in the United States and via prescription only in Europe.

METHODS: A semi-structured interview guide was developed based on a targeted literature review. Interviews were conducted with ophthalmologists in the US (n=4), Spain (n=4), Portugal (n=4), and France (n=4) who had experience treating CH with a range of treatments, including brimonidine tartrate (0.025%). Interview topics included CH pathology, treatment decisions, unmet needs, and treatment satisfaction. Interviews were recorded, transcribed verbatim, and analyzed using content analysis. This study received ethical review exemption from the WCG Institutional Review Board.

RESULTS: HCPs had 14–25 years' experience treating CH and treated 40–100 patients with CH in the prior month. HCPs reported limitations with existing treatments, such as eye sensitivity and rebound redness. Brimonidine tartrate (0.025%) was reported to be fast-acting and to cause fewer adverse events. HCPs emphasized the importance of determining and treating the cause of CH but noted brimonidine tartrate (0.025%) was a well-tolerated adjunctive option. In Europe, it was suggested that while prescription-only status reduces accessibility, it helps ensure HCPs monitor the cause of CH. Conversely, US HCPs stated that while over-the-counter availability increased accessibility, it was harder to monitor patient usage.

CONCLUSIONS: HCP experience of the current treatment landscape has previously been limited to treatments with short-term efficacy and adverse events. Brimonidine tartrate (0.025%) provides an effective and well-tolerated solution that addresses the aesthetic needs of patients with CH. HCPs highlight the need to identify and treat the underlying cause of CH, but report brimonidine tartrate (0.025%) can be used as an adjunctive treatment.